Literature DB >> 16275953

Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats.

Kemal Karaca1, David E Swayne, Deborah Grosenbaugh, Michel Bublot, Amy Robles, Erica Spackman, Robert Nordgren.   

Abstract

Vaccination of cats with fowlpox virus expressing the avian influenza (AI) virus H5 hemagglutinin gene (TROVAC AI) resulted in detectable hemagglutination inhibition (HI) antibody responses to the homologous A/Turkey/Ireland/1378/83 (H5N8) (A/tky/Ire/83) AI virus antigen. The HI antibody responses to heterologous A/Chicken/Indonesia/7/03 (H5N1) (A/ck/Indonesia/03) AI virus antigen were also detected in all vaccinated cats, but only after booster vaccinations. The vaccine described in this study and other poxvirus-vectored vaccines may be of value for the prophylaxis of AI virus-associated morbidity and mortality in mammals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275953      PMCID: PMC1287764          DOI: 10.1128/CDLI.12.11.1340-1342.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  16 in total

Review 1.  Influenza vaccines: present and future.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Safety profile of recombinant canarypox HIV vaccines.

Authors:  Guy de Bruyn; Anthony J Rossini; Ya-Lin Chiu; Drienna Holman; Marnie L Elizaga; Sharon E Frey; Donald Burke; Thomas G Evans; Lawrence Corey; Michael C Keefer
Journal:  Vaccine       Date:  2004-01-26       Impact factor: 3.641

3.  Avian H5N1 influenza in cats.

Authors:  Thijs Kuiken; Guus Rimmelzwaan; Debby van Riel; Geert van Amerongen; Marianne Baars; Ron Fouchier; Albert Osterhaus
Journal:  Science       Date:  2004-09-02       Impact factor: 47.728

Review 4.  Equine viral vaccines: the past, present and future.

Authors:  Jules Maarten Minke; Jean-Christophe Audonnet; Laurent Fischer
Journal:  Vet Res       Date:  2004 Jul-Aug       Impact factor: 3.683

5.  Recombinant fowlpox virus inducing protective immunity in non-avian species.

Authors:  J Taylor; R Weinberg; B Languet; P Desmettre; E Paoletti
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

6.  Protective immunity against avian influenza induced by a fowlpox virus recombinant.

Authors:  J Taylor; R Weinberg; Y Kawaoka; R G Webster; E Paoletti
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

7.  [Avian influenza and oseltamivir; a retrospective view].

Authors:  J M Galama
Journal:  Ned Tijdschr Geneeskd       Date:  2003-06-07

8.  Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).

Authors:  T-M Jourdier; C Moste; M-C Bonnet; F Delisle; J-P Tafani; P Devauchelle; J Tartaglia; P Moingeon
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

Review 9.  Are we ready for pandemic influenza?

Authors:  Richard J Webby; Robert G Webster
Journal:  Science       Date:  2003-11-28       Impact factor: 47.728

10.  Probable tiger-to-tiger transmission of avian influenza H5N1.

Authors:  Roongroje Thanawongnuwech; Alongkorn Amonsin; Rachod Tantilertcharoen; Sudarat Damrongwatanapokin; Apiradee Theamboonlers; Sunchai Payungporn; Kamonchart Nanthapornphiphat; Somchuan Ratanamungklanon; Eakchai Tunak; Thaweesak Songserm; Veravit Vivatthanavanich; Thawat Lekdumrongsak; Sawang Kesdangsakonwut; Schwann Tunhikorn; Yong Poovorawan
Journal:  Emerg Infect Dis       Date:  2005-05       Impact factor: 6.883

View more
  11 in total

Review 1.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

2.  Characterization of host responses against a recombinant fowlpox virus-vectored vaccine expressing the hemagglutinin antigen of an avian influenza virus.

Authors:  Hamid R Hghihghi; Leah R Read; Hakimeh Mohammadi; Yanlong Pei; Claudia Ursprung; Eva Nagy; Shahriar Behboudi; S M Mansour Haeryfar; Shayan Sharif
Journal:  Clin Vaccine Immunol       Date:  2010-01-13

Review 3.  H5N1 viruses and vaccines.

Authors:  Kanta Subbarao; Catherine Luke
Journal:  PLoS Pathog       Date:  2007-03       Impact factor: 6.823

Review 4.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

Review 5.  Animal models for the study of influenza pathogenesis and therapy.

Authors:  Dale L Barnard
Journal:  Antiviral Res       Date:  2009-01-25       Impact factor: 5.970

6.  Phylogenetic analysis of three genes of Penguinpox virus corresponding to Vaccinia virus G8R (VLTF-1), A3L (P4b) and H3L reveals that it is most closely related to Turkeypox virus, Ostrichpox virus and Pigeonpox virus.

Authors:  Olivia Carulei; Nicola Douglass; Anna-Lise Williamson
Journal:  Virol J       Date:  2009-05-08       Impact factor: 4.099

7.  New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.

Authors:  Jörg Rohde; Ralf Amann; Hanns-Joachim Rziha
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

Review 8.  Viral vector-based influenza vaccines.

Authors:  Rory D de Vries; Guus F Rimmelzwaan
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

Review 9.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

10.  A gene-based avian influenza vaccine in poultry.

Authors:  S S Rao; D Styles; W Kong; C Andrews; J P Gorres; G J Nabel
Journal:  Poult Sci       Date:  2009-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.